Amylyx Pharmaceuticals heads into its August 6 earnings report with the most prominent recent signal coming from the analyst community, not the short-selling camp.
Citigroup raised its price target on AMLX to $26 from $20 yesterday, maintaining a Buy rating — a move that arrives just one session before the print and resets the immediate-term reference point for bulls. The broader analyst trend reinforces the direction: Mizuho lifted its target to $24 in mid-July, and Guggenheim pushed its target to $40 in late June. The consensus mean price target now sits at $25.56, roughly 27% above the current price of $20.17. Targets range widely across the coverage universe, with Guggenheim's $40 sitting well above the consensus — but the directional message from the Street is consistent: multiple firms have revised upward over the past two months without touching their ratings.
The bull case centres on avexitide pricing power. Amylyx updated its model to a $183,333 annual WAC per patient, implying roughly $110,000 in net revenue per patient per year. Bulls argue that market penetration assumptions are conservative — capturing just 30% of the opportunity by 2040 — and that positive dialogue with the GLP-1 antagonist partner GUBRA underpins the longer-term pipeline story. Bears push back hard on the Phase 3 ALS data risk, noting that any shortfall in efficacy or safety relative to expectations could unwind the 68% year-to-date run in one session. The stock is up 10% over the past month alone, so the earnings bar is not a low one. EPS momentum factor scores are firm at 78 over 30 days and 72 over 90 days, suggesting the Street has been nudging estimates higher — but forward EPS remains deeply negative and declining year-on-year, limiting valuation support on fundamental multiples.
Short interest tells a less alarming story than the elevated headline figure suggests. Bears hold 11.2% of the free float short — high by absolute standards — but that position has been collapsing fast. Short interest fell roughly 14% in the past week after sitting near 14.5 million shares through most of July, dropping sharply after July 22. The lending market is not under any pressure: availability is extremely loose at 950%, meaning roughly nine shares are available to borrow for every one already lent out, and the cost to borrow has slipped to just 0.55%, down 20% on the week. Short sellers are retreating, not pressing. That dynamic has coincided with a recovering stock price but leaves the stock without a meaningful squeeze catalyst. Options positioning has tilted modestly more defensive into the print — the put/call ratio is 0.53, about one standard deviation above its 20-day average of 0.38, not an extreme read but higher than the subdued hedging seen through most of June and early July.
The last earnings event in May sent the stock down 8% on the day and 14% over the following five days, making Thursday's print a direct test of whether avexitide's revised pricing assumptions and the pipeline narrative can hold up under scrutiny at a price roughly 45% higher than where those declines were absorbed.
See the live data behind this article on ORTEX.
Open AMLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
